Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.52 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6464939 | 1.00 | NFE2L2 (0.64) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL3673865 | 1.00 | NFE2L2 (0.64) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL22468800 | 0.86 | NFE2L2 (0.78) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL700052 | 0.86 | NFE2L2 (0.78) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL13766558 | 0.86 | NFE2L2 (0.78) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL700051 | 0.86 | NFE2L2 (0.78) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL13766470 | 0.86 | NFE2L2 (0.78) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL3679884 | 0.84 | PTGS1 (0.84) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL18003161 | 0.84 | NFE2L2 (0.53) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL3679880 | 0.84 | PTGS1 (0.84) | NFE2L2PTGS1PTGS2NQO2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753708-A4 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2007-12-26 | — | — | EP | claimed |
| EP-1753708-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | Brigham Young University (US) | 2007-02-21 | — | — | EP | claimed |
| WO-2005069998-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY TECHNOLOGY TRANSFER OFFICE (US) | 2005-08-04 | — | — | WO | claimed |
| EP-1753708-B1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2018-02-21 | — | — | EP | disclosed |
| US-8841477-B2 | Sirtuin activating compounds and processes for making the same | BRIGHAM YOUNG UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY (US) | 2010-07-22 | — | — | US | disclosed |
| US-7714161-B2 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| EP-1585713-A1 | NEW STILBENE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR LIGAND ANTAGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2005-10-19 | — | — | EP | disclosed |
| US-20040147788-A1 | Stilbene derivatives and their use as aryl hydrocarbon receptor antagonistic ligands | INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M.) (FR) | 2004-07-29 | — | — | US | disclosed |
| WO-2004041758-A1 | NEW STILBENE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR LIGAND ANTAGONISTICS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M.) (FR) | 2004-05-21 | — | — | WO | disclosed |
| EP-1418164-A1 | New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2004-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147788-A1 | Stilbene derivatives and their use as aryl hydrocarbon receptor antagonistic ligands | AHR, HCAR3, HCAR1 | NFE2L2 530/4885PTGS1 2187/4885PTGS2 2185/4885 |
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | SIRT1, SIRT2, SIRT3 | NFE2L2 144/4885PTGS1 4110/4885PTGS2 3384/4885 |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | RB1, SBK1, NADK | NFE2L2 290/4885PTGS1 3702/4885PTGS2 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.